Karyopharm outlines $1B peak U.S. revenue opportunity in myelofibrosis with pivotal Phase III data expected by March 2026 Karyopharm outlines $1B peak U.S. revenue opportunity in myelofibrosis with pivotal Phase III data expected by March 2026 Post ContentkptiRead More You might also be interested in reading New Gemini call/email scam!. August 11, 2025 In Mainstream ← Previous post Next post →